All figures in this presentation are unaudited and provisional.
EIB at a Glance

Improving quality of life in Europe and beyond

The world’s largest multilateral lender
We raise our funds on the international capital markets
We pass on favourable borrowing conditions

Governed by the EU Member States
Shareholders are the EU 27 Member States

Headquartered in Luxembourg
Around 3,400 staff in 50 global offices

Leading provider of climate finance
€36.5 bn in climate action investments in 2022

In 60 years, over €1.2 trillion invested
More than 12,000 projects in over 160 countries
Crowding-in bank: €3 trillion investment mobilised

€72.45 billion in financing in 2022

Our Priorities

INNOVATION, DIGITAL AND HUMAN CAPITAL

€17.93 Bn

SUSTAINABLE ENERGY AND NATURAL RESOURCES

€20.86 Bn

SUSTAINABLE CITIES AND REGIONS

€17.31 Bn

SMES AND MID CAPS

€16.35 Bn
Eligibility Criteria
Financing for Impact

EU Policy Goals (External)
- Technically Feasible
- Economically Sustainable
- Financially Viable
- Environmentally Sound
- Socially Acceptable

Technical soundness, risks and mitigation measures, capacity for products/services

Promoter capability to implement, operate and maintain project

Timing, employment, operating and maintenance costs, comparison with costs of similar projects

Compliance with applicable legislation and EIB guidelines on procurement, environmental and social aspects

Analysis of market and demand

Economic and financial profitability (e.g. rate of return)
What do we Finance in Life Science Projects?

**Infrastructure** – buildings, furnishings, validation

**Innovation** – R&D, clinical trials, regulatory, market access

**Digitalisation & Technology Transfer**

**Medicinal Products, Medical Devices, Diagnostics...**

**Therapeutic Indication Agnostic** – Unmet medical need
Recent EIB Life Science Projects OEU

- In Africa
  - Egypt
  - Ghana
  - Rwanda
  - Senegal
  - South Africa

- In discussion for LATAM and Caribbean
MADIBA Project - Senegal

€ 75 million financing to support Institut Pasteur de Dakar.

Loan facility to finance IPD’s new vaccine manufacturing facility in Senegal.

The facility is expected to contribute to reducing Africa’s dependence on imported vaccines and support equal access to vaccines.
Biovac – South Africa

€ 15 million grant financing to support investments in vaccine manufacturing in partnership with the European Commission.

A facility to support the expansion of Biovac’s manufacturing facilities in the Western Cape, South Africa. Includes the furnishing and validation of a commercial scale manufacturing facility for human health vaccines.

The facilities are expected to have capability at end state, to manufacture both Drug Substance and Drug Product. Initially targeting priority vaccines for the African continent. The project is an important contributor to the biotech ecosystem.
DEK Vaccines - Ghana

€ 5 million grant financing to provide seed financing, as part of Team Europe Initiative.

The project supports the design and development of a fill and finish facility for sterile human medicinal products, including vaccines.

The project is expected to help fill an important market gap in relieving Africa’s dependency on vaccine imports. Impacts are expected on pharmaceutical supply chain resilience, and independent health security.
Thank You